BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Treeline Biosciences

1 post

Treeline Biosciences is a biotechnology company founded by Josh Bilenker, M.D. and Jeff Engelman M.D., Ph.D. The name was curated to connote the concept of the outer limits of scientific possibilities, the places where conditions are a challenge but the metaphorical trees and forests still thrive and grow.

Treeline Biosciences is focused on oncology molecular targets that are currently validated but have to date been difficult to successfully drug. Treeline Biosciences believes their unique approach may further be applied to other areas of therapeutics as well.

Former Lilly CEO Josh Bilenker & Former Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences

Biotech NewsEx-Lilly CEO Josh Bilenker & Ex-Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences

  • BioTech Health X
  • April 30, 2021
Two powerhouse executives have joined forces to form a brand new cancer Biotech company. Josh Bilenker, M.D., and…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Johnson & Johnson (JNJ) Flexes Its Oncology Muscle With 16.4% Sales Growth
  • Would You Still Dare to Invest in Revolution Medicines (RVMD)?
  • Merck (MRK) Has an $8.6 Billion Cancer Franchise and a Succession Plan to Prove
  • AbbVie (ABBV) Delivers $17.4 Billion in Revenue
  • Pfizer (PFE) Gets an Oncology Boost as Padcev Sales Surge 55%
Featured Posts
    • November 6, 2026
    Johnson & Johnson (JNJ) Flexes Its Oncology Muscle With 16.4% Sales Growth
    • November 6, 2026
    Would You Still Dare to Invest in Revolution Medicines (RVMD)?
    • November 6, 2026
    Merck (MRK) Has an $8.6 Billion Cancer Franchise and a Succession Plan to Prove
    • November 6, 2026
    AbbVie (ABBV) Delivers $17.4 Billion in Revenue
    • November 6, 2026
    Pfizer (PFE) Gets an Oncology Boost as Padcev Sales Surge 55%
Recent Posts
  • Guardant Health (GH) Posts 44% Revenue Growth as Liquid Biopsy Gains Ground
    • November 6, 2026
  • Natera (NTRA) Gets a Growth Spurt as Cancer Testing Volume Jumps 57%
    • November 6, 2026
  • Is it Still a Wise Move to Invest in Cogent Biosciences (COGT)?
    • November 6, 2026
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (6)
  • Biotech News (1,185)
  • Uncategorized (2)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top